title: Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection.
abstract: OBJECTIVE
  To evaluate outcome and prognostic factors in patients with locally advanced gastric cancer.
  
  
  METHODS
  From 2007 to 2011, 55 patients underwent adjuvant radiotherapy and concurrent chemotherapy with 5-fluorouracil (64%) or capecitabine (36%). D2 node resection was performed in all patients. The pathological stage was as follows: 13% IB; 29% II; 24% IIIA; 9% IIIB and 25% stage IV.
  
  
  RESULTS
  The median follow up was 21 months. Five-years overall and disease-free survival were 44.5% and 48%, respectively. Eighteen patients experienced disease relapse after combined treatment; in five of these patients, relapse was both locoregional and systemic. The most common toxicity was grade 1-2 leukopenia, reported in 32% of cases. Six patients developed grade 3 toxicity. Nodal ratio ≥0.4 and N3 stage were significant prognostic factors for survival and relapse.
  
  
  CONCLUSIONS
  Adjuvant conformal radiotherapy and concurrent chemotherapy is a feasible and well-tolerated treatment for patients with locally advanced gastric cancer.
authors.affiliation: Institute of Radiation Oncology, La Sapienza University, Sant’Andrea Hospital, Rome, Italy.
authors.forename: Mattia Falchetto
authors.initials: MF
authors.lastname: Osti
authors.forename: Linda
authors.initials: L
authors.lastname: Agolli
authors.forename: Stefano
authors.initials: S
authors.lastname: Bracci
authors.forename: Flavia
authors.initials: F
authors.lastname: Monaco
authors.forename: Slavisa
authors.initials: S
authors.lastname: Tubin
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Minniti
authors.forename: Vitaliana
authors.initials: V
authors.lastname: De Sanctis
authors.forename: Riccardo Maurizi
authors.initials: RM
authors.lastname: Enrici
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil